J&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab...
Thursday, August 30, 2012, 8:16 AM ETJ&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles